PPCB

Propanc Biopharma Inc (PK)
0.0006
0.00 (0.00%)

Period:

Draw Mode:

Volume 30,962,098
Bid Price 0.0005
Ask Price 0.0006
News -
Day High 0.0006

Low
0.0002

52 Week Range

High
0.0339

Day Low 0.0005
Company Name Stock Ticker Symbol Market Type
Propanc Biopharma Inc (PK) PPCB OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.0006 15:50:15
Open Price Low Price High Price Close Price Prev Close
0.0006 0.0005 0.0006 0.0006 0.0006
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
46 30,962,098 $ 0.000558 $ 17,277 - 0.0002 - 0.0339
Last Trade Time Type Quantity Stock Price Currency
15:50:15 999,999 $ 0.0006 USD

Propanc Biopharma Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.41M 2.35B 100.62M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
31.36k $ - - - -

more financials information »

Propanc Biopharma (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PPCB Message Board. Create One! See More Posts on PPCB Message Board See More Message Board Posts

Historical PPCB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00070.00080.00040.000636386,990,095-0.0001-14.29%
1 Month0.00040.00110.00030.0007226115,805,4100.000250.0%
3 Months0.00060.00110.00020.000595571,906,5820.000.0%
6 Months0.00180.00180.00020.000672544,487,304-0.0012-66.67%
1 Year0.01880.03390.00020.001668432,581,895-0.0182-96.81%
3 Years0.0320.700.00020.002923115,027,540-0.0314-98.13%
5 Years0.102.570.00020.009110910,268,437-0.0994-99.4%

Propanc Biopharma (PK) Description

Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers. The Company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.